United States· US:0078-1217_ade5aa80-b303-470f-8e79-7edea0c4a1bc
PLUVICTO
A medicinal product containing lutetium lu-177 vipivotide tetraxetan, registered in United States by Novartis Pharmaceuticals Corporation.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc110078-1217-61
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lutetium lu-177 vipivotide tetraxetan in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandPluvicto 1000 MBq/ml, Injektions-/InfusionslösungNovartis Pharma Schweiz AG
- CanadaPLUVICTONOVARTIS PHARMACEUTICALS CANADA INC
- CzechiaPLUVICTONovartis Europharm Limited, Dublin
- FinlandPluvictoNovartis Europharm Limited
- FrancePLUVICTO 1 000 MBq/mL, solution injectable/pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- United KingdomPluvicto 7,400MBq/7.5-12.5ml solution for injection vialsNovartis Pharmaceuticals UK Ltd
- IrelandPluvicto 1000 MBq/mL solution for injection/infusionNovartis Europharm Limited
- IcelandPluvictoNovartis Europharm Limited*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Pluvicto
- Liechtenstein · Pluvicto
- Norway · Pluvicto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2d30c8f-41e4-4435-94dd-4255fad3df19 GET /v1/drugs/e2d30c8f-41e4-4435-94dd-4255fad3df19?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "27",
"substance": "LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN",
"productndc": "0078-1217",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mCi/mL",
"application_number": "NDA215833",
"marketing_category": "NDA"
}See everything about lutetium lu-177 vipivotide tetraxetan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.